ReEmerge Raises $37M to Advance Brain Injury Technology

Boston, Massachusetts, U.S., September 15, 2026

CNRT Targets Chronic Cognitive Impairment

Chronic cognitive impairment after brain injury can affect areas such as memory, attention, processing speed, executive function, and the ability to perform everyday activities. While some individuals recover substantially following an injury, others continue to experience symptoms for months or years. ReEmerge is focused on this persistent population and is developing CNRT as a potential intervention for patients whose cognitive difficulties remain after the acute phase of injury. The company’s technology is based on non-invasive neuromodulation, an approach that uses controlled stimulation to influence activity within neural circuits. ReEmerge’s platform is designed to target brain networks associated with cognition and functional performance. Rather than relying on medication to modify biochemical pathways, the technology seeks to influence neural activity through externally delivered stimulation. The company believes that persistent cognitive impairment following brain injury represents an area where additional therapeutic options are needed. Its development strategy is focused on translating advances in neuroscience and brain-network research into an intervention that can be evaluated in clinical settings.

$37 Million Financing Supports Clinical Development

The $37 million Series A financing provides ReEmerge with capital to advance CNRT and expand its clinical-development activities. The round was described as oversubscribed, indicating that the financing attracted commitments exceeding the company’s original fundraising target. The company plans to use the proceeds to support clinical studies, technology development, regulatory activities, and organizational growth. Financing is an important component of medical-device development because technologies intended for neurological applications generally require extensive clinical validation, safety evaluation, regulatory review, and product development before broader commercialization. ReEmerge’s emergence from stealth marks the beginning of a more public phase of its development program and provides additional visibility into its technology and therapeutic objectives. The company has assembled a multidisciplinary team that includes specialists in neuroscience, medicine, engineering, and commercialization. ReEmerge said its leadership and scientific collaborators have experience developing technologies and therapies intended to address neurological disorders and unmet clinical needs.

Advancing Brain Injury Treatment Research

ReEmerge’s CNRT platform is being developed against a backdrop of increasing research into brain network dysfunction and neuroplasticity. Following brain injury, disruptions to neural networks can affect communication between different regions involved in cognitive processing. Researchers are investigating whether targeted neuromodulation can help influence these networks and promote functional recovery. The company’s approach is intended to leverage the brain’s capacity for neuroplasticity, through which neural circuits can adapt and reorganize in response to changes or stimulation. The goal of CNRT is to investigate whether appropriately targeted stimulation can improve the function of neural networks associated with cognition. However, the company’s technology remains under development, and clinical research will be necessary to establish its safety and effectiveness. Early scientific rationale or preliminary findings do not establish that the therapy will provide meaningful benefits for all patients with chronic cognitive impairment.

The financing will enable ReEmerge to continue evaluating its platform and generate additional clinical evidence. Future studies are expected to provide information about patient selection, treatment protocols, safety, cognitive outcomes, and durability of treatment effects. These data will be important for determining the potential clinical role of CNRT and supporting future regulatory discussions. The company’s emergence from stealth and Series A financing highlight increasing investment in neurological medical technology and brain-health innovation. Chronic cognitive impairment following brain injury remains a complex clinical challenge, and technologies that seek to modulate neural circuits represent one avenue of ongoing research. ReEmerge’s development program therefore represents a notable MedTech initiative in neurorehabilitation and cognitive health. With $37 million in new financing, the company intends to advance its CNRT platform through further development and clinical evaluation. As research progresses, clinical evidence will determine whether the technology can provide a safe and effective approach for addressing persistent cognitive impairment associated with brain injuries.

Source: ReEmerge press release